Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Ida T, Furuta S, Fujiwara M, Hiraguri M, Hirose K, Ikeda K, Iwamoto T, Kagami SI, Kobayashi Y, Kurasawa K, Nakagomi D, Oya Y, Sanayama Y, Shimizu T, Tamachi T, Umibe T, Yasui M, Nakajima H. Ida T, et al. Among authors: oya y. Rheumatology (Oxford). 2024 Jan 12:keae011. doi: 10.1093/rheumatology/keae011. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38216799
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S, Sugiyama T, Umibe T, Kaneko Y, Amano K, Kurasawa K, Nakagomi D, Hiraguri M, Hanaoka H, Sato Y, Ikeda K, Nakajima H; LoVAS Trial study investigators. Furuta S, et al. BMJ Open. 2017 Dec 14;7(12):e018748. doi: 10.1136/bmjopen-2017-018748. BMJ Open. 2017. PMID: 29247107 Free PMC article. Clinical Trial.
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC.
Akao K, Oya Y, Sato T, Ikeda A, Horiguchi T, Goto Y, Hashimoto N, Kondo M, Imaizumi K. Akao K, et al. Among authors: oya y. Explor Target Antitumor Ther. 2024;5(4):826-840. doi: 10.37349/etat.2024.00251. Epub 2024 Jul 19. Explor Target Antitumor Ther. 2024. PMID: 39280252 Free PMC article. Review.
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K. Kawachi H, et al. Among authors: oya y. Clin Lung Cancer. 2024 Nov;25(7):643-652.e4. doi: 10.1016/j.cllc.2024.07.014. Epub 2024 Jul 25. Clin Lung Cancer. 2024. PMID: 39138106
291 results